ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0823

Sleep Disturbance Predicts Pain Interference in Patients with Early Rheumatoid Arthritis in a Prospective Real-World Cohort

Burcu Aydemir1, Orit Schieir2, Marie-France Valois3, Lutfiyya Muhammad1, Jing Song1, dorothy Dunlop1, Susan Bartlett4, Louis Bessette5, Gilles Boire6, Glen Hazelwood7, Carol Hitchon8, Edward Keystone9, Janet Pope10, Carter Thorne11, Diane Tin12, Vivian Bykerk13, Yvonne Lee14 and Canadian Early Arthritis Cohort (CATCH) Investigators15, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2McGill University, Montréal, QC, Canada, 3McGill University, Pointe-Claire, QC, Canada, 4McGill University, Montreal, QC, Canada, 5Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, 6Université de Sherbrooke, Sherbrooke, QC, Canada, 7University of Calgary, Calgary, AB, Canada, 8University of Manitoba, Manitoba, MB, Canada, 9Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 10University of Western Ontario, London, ON, Canada, 11Southlake Regional Health Centre, Newmarket, ON, Canada, 12Newmarket Rheumatology Consultants, Newmarket, ON, Canada, 13Department of Rheumatology, Hospital for Special Surgery, New York, NY, 14Northwestern University, Chicago, IL, 15CATCH, Winnipeg, MB, Canada

Meeting: ACR Convergence 2023

Keywords: Cohort Study, pain, Patient reported outcomes, rheumatoid arthritis, sleep

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: Patient Outcomes, Preferences, & Attitudes I: Assessment Tools

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Despite taking strong immunosuppressive medications to control inflammation, many patients with rheumatoid arthritis (RA) continue to experience moderate to severe pain that does not correlate with laboratory or clinical findings. Sleep disturbances are extensively reported among patients with RA and could influence pain perception. Prior investigations have demonstrated that one night of partial sleep loss is associated with increases in next day pain in patients with RA. However, there is a knowledge gap regarding the impact of sleep disturbances on long-term pain outcomes. The objective of the present study was to determine whether sleep disturbances early in the disease are associated with future pain interference.

Methods: Data were from adults with early RA (joint symptoms ≤12 months) enrolled in the Canadian Early Arthritis Cohort between 2016-2023 who completed PROMIS (Patient-Reported Outcomes Measurement Information System) measures at 0, 6-, 12-, 18-, and 24-months to assess sleep disturbance (primary predictor) and pain interference (primary outcome). PROMIS sleep disturbance assesses perceptions of sleep quality, depth, and restoration. PROMIS pain interference measures the extent to which pain interferes with physical, mental, and social functioning. To estimate longitudinal associations between sleep disturbance and pain interference, the dataset was lagged so that repeat measures of sleep disturbance at 0, 6, 12 and 18 months were specified to predicted pain interference 6-months later at 6-,12-, 18- and 24-months follow up. Linear mixed effects regression was used to estimate crude and adjusted effects of sleep disturbance on pain interference over the 24-month study period adjusted for age, sex, body mass index (BMI), education, income, smoking status, comorbidity index, steroid use, and treatment.

Results: The sample included 502 patients with early RA. At baseline, the sample was 68% female, 81% Caucasian, 73% seropositive (RF/ACPA), and 77% met the 1987 ARA Classification Criteria for RA or the 2010 ACR/EULAR RA Classification Criteria; with a mean (SD) age of 56 (14) years, BMI of 28.4 (6.7) kg/m2,and disease duration of 5.4 (2.9) months (Table 1). The mean (SD) T-score for PROMIS pain interference was 60.4 (8.6) and PROMIS sleep disturbance was 53.5 (8.5) at baseline (Figure 1). The unadjusted and adjusted linear mixed effects regression models revealed a significant association between sleep disturbance and pain interference scores, indicating that better sleep 6-months prior was associated with less pain interference at the following 6-month evaluation (Table 2).

Conclusion: In this cohort of patients with early RA, more disturbed sleep predicted greater pain interference 6 months later. These findings underscore the importance of addressing sleep disturbances as part of pain management strategies. Identifying and targeting problematic sleep disturbances early on may help improve long-term pain outcomes. Further work is needed to explore the underlying mechanisms and to investigate potential interventions targeting sleep to alleviate pain in RA.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: B. Aydemir: None; O. Schieir: None; M. Valois: None; L. Muhammad: None; J. Song: None; d. Dunlop: None; S. Bartlett: Janssen, 6, Merck/MSD, 2, 6, Novartis, 2, Organon, 1, 6, PROMIS Health Organization, 4, Sandoz, 2, 6; L. Bessette: AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Bristol Myers Squibb, 2, 5, 6, Eli Lilly, 2, 5, 6, Fresenius Kabi, 2, 6, Gilead, 2, 5, 6, JAMP Pharma, 2, 5, 6, Janssen, 2, 5, 6, Novartis, 2, 5, 6, Organon, 2, 6, Pfizer, 2, 5, 6, Sandoz, 2, 6, Sanofi, 2, 5, 6, Teva, 2, 6, UCB, 2, 5, 6, UCBA, 5; G. Boire: Eli Lilly, 1, Janssen, 6, Organon, 1, Orimed Pharma, 1, 6, Otsuka, 1, Pfizer, 1, 5, Sandoz, 1, Teva, 1, Viatris, 1, 6; G. Hazelwood: None; C. Hitchon: Astra Zeneca, 1, Pfizer Canada, 5; E. Keystone: AbbVie/Abbott, 2, 6, Amgen, 2, 6, celltrion, 2, 6, Eli Lilly, 2, 6, Fresenius Kabi, 2, 6, Pfizer, 2, 6, Samsung Bioepsis, 2, sandoz, 2, 6; J. Pope: AbbVie, 1, 2; C. Thorne: Abbvie, 1, Biogen, 2, Nordic Pharma, 1, Pfizer, 1, 5, Roche, 1, Sandoz, 1, 2; D. Tin: None; V. Bykerk: AbbVie, 2, Bristol Myers Squibb, 1, 2, 5, Pfizer, 1, 2; Y. Lee: Cigna-Express Scripts, 8, Eli Lilly, 12, Medical Writer, Pfizer, 5, Sanofi, 12, Medical Writer; C. (CATCH) Investigators: AbbVie Corporation, 5, Amgen Canada, 5, Hoffman La Roche Limited, 5, Medexus Pharmaceuticals, 5, Organon Canada, 5, Pfizer Canada, 5, Sandoz Biopharmaceuticals Canada, 5.

To cite this abstract in AMA style:

Aydemir B, Schieir O, Valois M, Muhammad L, Song J, Dunlop d, Bartlett S, Bessette L, Boire G, Hazelwood G, Hitchon C, Keystone E, Pope J, Thorne C, Tin D, Bykerk V, Lee Y, (CATCH) Investigators C. Sleep Disturbance Predicts Pain Interference in Patients with Early Rheumatoid Arthritis in a Prospective Real-World Cohort [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/sleep-disturbance-predicts-pain-interference-in-patients-with-early-rheumatoid-arthritis-in-a-prospective-real-world-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sleep-disturbance-predicts-pain-interference-in-patients-with-early-rheumatoid-arthritis-in-a-prospective-real-world-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology